Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enalapril + lercanidipine (Multicare Pharma)
- Development stage
- Discontinued
- Lead developer
- Multicare Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Care Dipine Plus is a fixed-dose combination antihypertensive medication developed and marketed by Multicare Farmacéutica. It contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor, and lercanidipine hydrochloride, a dihydropyridine calcium channel blocker. The combination is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled by lercanidipine or enalapril monotherapy. Enalapril works by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone secretion, while lercanidipine inhibits the influx of extracellular calcium into vascular smooth muscle and cardiac cells, causing peripheral vasodilation. Together, these complementary mechanisms of action provide synergistic blood pressure reduction with a favorable tolerability profile.
- Brand names
- Care Dipine Plus
- Other names
- enalapril maleate + lercanidipine hydrochloridelercanidipine + enalapril
02
Targets
ACE (Angiotensin Converting Enzyme)CA2 (Carbonic Anhydrase 2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)POT (Proton-coupled oligopeptide transporter)
Beyond the preview
Go deeper on enalapril + lercanidipine (Multicare Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enalapril + lercanidipine (Multicare Pharma).